AstraZeneca's hopes of developing its PD-L1 inhibitor Imfinzi for cervical cancer have been hit by a failed phase 3 trial of the drug alongside chemotherapy as a first-line treatment for women ...

AstraZeneca said the safety and tolerability profile for Truqap was consistent with other trials. This is another blow for one of AstraZeneca’s flagship oncology ... negative breast cancer (TNBC). In ...

A new commercial for AstraZeneca’s Truqap ... breast cancer who have experienced recurrence or progression on other treatments. The approval was based on study data showing that the drug combo ...

A cancer drug from partners AstraZeneca and Daiichi Sankyo currently approved as a second-line or later treatment for metastatic breast cancer ... Enhertu’s label carries a black box warning ...

AstraZeneca’s immunotherapy combination including its checkpoint inhibitor drug Imfinzi has failed to improve overall survival in a first-line lung cancer trial – an indication where Merck ...

AstraZeneca ... drug cocktail when it was combined with another medicine, Pertuzumab. The trial was testing Enhertu’s effectiveness against HER2-positive metastatic breast cancer.

Also Read: European Drug Regulator Approves AstraZeneca’s Two Flagship Cancer Drugs For Breast And Lung Cancer Settings The PFS improvement was seen across all pre-specified patient subgroups ...

AstraZeneca (NASDAQ ... improvement as a first line treatment of metastatic breast cancer, compared to standard care. Enhertu, an antibody drug conjugate, is being jointly developed and ...

AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been approved by the European Commission (EC) for use in certain cases of pre-treated breast cancer. The drug has been ...